IQ EQ FUND MANAGEMENT IRELAND Ltd Purchases 184,757 Shares of 10x Genomics $TXG

IQ EQ FUND MANAGEMENT IRELAND Ltd grew its holdings in 10x Genomics (NASDAQ:TXG) by 176.8% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 289,269 shares of the company’s stock after purchasing an additional 184,757 shares during the quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd owned approximately 0.23% of 10x Genomics worth $3,350,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also modified their holdings of the business. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in 10x Genomics by 235.6% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,103,768 shares of the company’s stock valued at $62,016,000 after buying an additional 4,987,195 shares during the period. Millennium Management LLC raised its position in shares of 10x Genomics by 434.5% during the 1st quarter. Millennium Management LLC now owns 5,377,492 shares of the company’s stock valued at $46,946,000 after acquiring an additional 4,371,327 shares during the last quarter. Jacobs Levy Equity Management Inc. lifted its stake in shares of 10x Genomics by 3,619.6% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 1,166,723 shares of the company’s stock valued at $10,185,000 after purchasing an additional 1,135,356 shares during the period. ARK Investment Management LLC boosted its position in shares of 10x Genomics by 8.1% in the 2nd quarter. ARK Investment Management LLC now owns 13,892,103 shares of the company’s stock worth $160,871,000 after purchasing an additional 1,046,390 shares during the last quarter. Finally, Iron Triangle Partners LP acquired a new stake in shares of 10x Genomics during the first quarter worth $8,730,000. 84.68% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on TXG. Weiss Ratings reissued a “sell (d-)” rating on shares of 10x Genomics in a research note on Tuesday, October 14th. Barclays reaffirmed an “overweight” rating and issued a $15.00 price target (up from $13.00) on shares of 10x Genomics in a research note on Friday, August 8th. Morgan Stanley reduced their price objective on shares of 10x Genomics from $18.00 to $17.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 12th. Canaccord Genuity Group set a $16.00 price objective on shares of 10x Genomics in a report on Monday, August 11th. Finally, Wall Street Zen upgraded shares of 10x Genomics from a “hold” rating to a “buy” rating in a report on Friday, October 3rd. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, seven have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, 10x Genomics presently has a consensus rating of “Hold” and a consensus target price of $13.65.

10x Genomics Stock Performance

NASDAQ TXG opened at $13.59 on Tuesday. The stock has a market cap of $1.69 billion, a price-to-earnings ratio of -19.41 and a beta of 2.05. The business has a 50 day simple moving average of $12.88 and a 200 day simple moving average of $11.41. 10x Genomics has a 52-week low of $6.78 and a 52-week high of $18.21.

10x Genomics (NASDAQ:TXG) last announced its quarterly earnings results on Thursday, August 7th. The company reported $0.28 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.63. 10x Genomics had a negative net margin of 13.13% and a negative return on equity of 12.88%. The firm had revenue of $172.91 million for the quarter, compared to analyst estimates of $139.36 million. During the same quarter in the previous year, the firm posted ($0.32) earnings per share. The business’s revenue was up 12.9% on a year-over-year basis. 10x Genomics has set its Q3 2025 guidance at EPS. On average, analysts predict that 10x Genomics will post -1.43 EPS for the current year.

Insider Buying and Selling

In other news, CFO Adam Taich sold 22,315 shares of the business’s stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $13.79, for a total value of $307,723.85. Following the sale, the chief financial officer directly owned 309,273 shares in the company, valued at $4,264,874.67. The trade was a 6.73% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Serge Saxonov sold 9,348 shares of the company’s stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $13.79, for a total value of $128,908.92. Following the transaction, the chief executive officer directly owned 945,892 shares of the company’s stock, valued at $13,043,850.68. This represents a 0.98% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 39,149 shares of company stock valued at $539,865. Company insiders own 10.03% of the company’s stock.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.